Picture

Northwestern Medicine
​Breakthroughs for Physicians

​​
  • Home
  • Specialties
    • Cardiovascular >
      • Research
      • Clinical Breakthroughs
      • News
    • Endocrinology >
      • Clinical Breakthroughs In Endocrinology
      • Research In Endocrinology
      • News
    • ENT (Otolaryngology) >
      • Clinical Breakthroughs
      • Research
      • News
    • Gastroenterology >
      • Clinical Breakthroughs
      • Research
      • News
    • Geriatrics >
      • Clinical Breakthroughs
      • Research
      • News
    • Neurosciences >
      • Rare and Complex Brain Tumors
      • Research
      • COVID-19 and Neurosciences
      • News
      • Clinical Breakthroughs
    • OB-GYN >
      • Clinical Breakthroughs
      • Research
      • News
    • Oncology >
      • Clinical Breakthroughs
      • Research
      • News
    • Ophthalmology >
      • Clinical Breakthroughs
      • Research
      • News
    • Organ Transplant >
      • Clinical Breakthroughs
      • Research
      • News
    • Orthopaedics >
      • Clinical Breakthroughs
      • Research
      • News
    • Psychiatry >
      • Clinical Breakthroughs
      • Research
      • News
    • Pulmonary >
      • Clinical Breakthroughs
      • Research
      • News
    • Rehabilitation >
      • Clinical Breakthroughs
      • News
    • Rheumatology >
      • Clinical Breakthroughs
      • Research
      • News
    • Urology >
      • Clinical Breakthroughs
      • Research
      • News
  • CME
  • REFERRALS
    • Refer to NM Cardiovascular
    • Refer to NM Neurosciences
    • Refer to Other Specialties

< BACK TO RESEARCH IN UROLOGY

April 2024

UROLOGY

A NOVEL ROLE FOR EZH2 IN A-TO-I RNA EDITING IN PROSTATE CANCER

Featuring: Qi Cao, PhD

Prostate cancer is one of the most common cancers among men, and although it can successfully be treated in some men, others develop resistance to therapies and can relapse. Thus, it is prudent to discover new therapeutic targets and develop therapeutic strategies that utilize already developed therapies to expedite the development of new treatment options for prostate cancer patients.  

Prostate cancer can be caused at genetic and epigenetic levels. Not only do epigenetic modifications include unwinding of genes (i.e., DNA) so they can be expressed as RNA, but this epigenetic regulation can also edit RNA. One epigenetic modifier is protein enzyme enhancer of zest homolog 2 (EZH2) that normally modifies the histone H3K27, thereby, tightly winding DNA and silencing gene expression. Our previous work showed that EZH2 is upregulated in advanced prostate carcinomas and metastatic prostate cancer, and prostate cancer patients who have higher expression levels of EZH2 have shorter survival times than prostate cancer patients with low or no expression of EZH2. Surprisingly, we recently discovered that dysregulation of EZH2 alters RNA editing, which is totally different from its well-known canonical function as a protein modifier. RNA editing can affect the stability of RNA and induce variations, mutations, and truncations in the RNA, which alter important regulation of the RNA and protein translation fidelity. These aberrant effects on RNA by alterations in RNA editing are associated with cancer, in particular, prostate cancer. Therefore, investigating this novel EZH2 non-canonical function in RNA editing will help us better understand the progression of advanced prostate cancer. ​

 Although the development of EZH2 inhibitors has been an active area of investigation and multiple biotech and pharmaceutical companies have been developing such drugs, EZH2 inhibitors alone have not proven effective in most solid cancers. Thus, identifying new therapeutics targets will lead to the development of new drugs that can be combined with already developed drugs, hence, expediting the development of new treatment options for cancer. Our data show, for the first time, that EZH2 directly interacts with ADAR, which is an RNA-specific adenosine deaminase and one of two enzymes responsible for editing and converting adenosine to inosine in RNA. Most advanced prostate cancer cells have higher expression levels of EZH2 and ADAR compared to those in benign prostate epithelial cells and early-stage prostate cancer cells, suggesting the importance of both of these proteins in prostate cancer progression. In the proposed project, we will identify precisely how EZH2 and ADAR interact and edit the substrates in prostate cancer. Next, we will study how EZH2 and ADAR work together to promote prostate cancer progression. Understanding these mechanisms will lead to the future design of new inhibitors of EZH2 and ADAR. Therefore, our work provides a novel rationale to target both ADAR and EZH2, and we predict that the inhibition of both ADAR and EZH2 will kill more cancer cells than inhibiting either ADAR or EZH2 alone. 
​

Read more about this project. ​

​This article was originally published in the Feinberg School of Medicine Newsletter in April 16, 2024. 

Qi Cao, PhD headshot
Qi Cao, PhD, Anthony J. Schaeffer, MD, Professor of Urology, Associate Professor of Urology

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​
Call 312.695.8146
Find an NM Urologist

You May Also Like

physicians in OR

January 2024

UROLOGY
2023 Year in Review | Northwestern Medicine Urology
microscopic image

January 2024

UROLOGY
Special Considerations for HoLEP After Failed Prior BPH Surgery
Physicians in mask video still

November 2023

UROLOGY
Behind BETTER Medicine: Complex Robot-Assisted Ileal Conduit Revision Surgery

Northwestern Medicine Breakthroughs for Physicians

About Us     Terms of Use     Privacy Policy     How to Vote for U.S. News & World Report Best Hospitals
© 2025 Northwestern Medicine® and Northwestern Memorial HealthCare. 
Northwestern Medicine® is a trademark of Northwestern Memorial HealthCare, used by Northwestern University
Connect with us
[email protected]
International physicians, contact [email protected]
  • Home
  • Specialties
    • Cardiovascular >
      • Research
      • Clinical Breakthroughs
      • News
    • Endocrinology >
      • Clinical Breakthroughs In Endocrinology
      • Research In Endocrinology
      • News
    • ENT (Otolaryngology) >
      • Clinical Breakthroughs
      • Research
      • News
    • Gastroenterology >
      • Clinical Breakthroughs
      • Research
      • News
    • Geriatrics >
      • Clinical Breakthroughs
      • Research
      • News
    • Neurosciences >
      • Rare and Complex Brain Tumors
      • Research
      • COVID-19 and Neurosciences
      • News
      • Clinical Breakthroughs
    • OB-GYN >
      • Clinical Breakthroughs
      • Research
      • News
    • Oncology >
      • Clinical Breakthroughs
      • Research
      • News
    • Ophthalmology >
      • Clinical Breakthroughs
      • Research
      • News
    • Organ Transplant >
      • Clinical Breakthroughs
      • Research
      • News
    • Orthopaedics >
      • Clinical Breakthroughs
      • Research
      • News
    • Psychiatry >
      • Clinical Breakthroughs
      • Research
      • News
    • Pulmonary >
      • Clinical Breakthroughs
      • Research
      • News
    • Rehabilitation >
      • Clinical Breakthroughs
      • News
    • Rheumatology >
      • Clinical Breakthroughs
      • Research
      • News
    • Urology >
      • Clinical Breakthroughs
      • Research
      • News
  • CME
  • REFERRALS
    • Refer to NM Cardiovascular
    • Refer to NM Neurosciences
    • Refer to Other Specialties